NASDAQ:DRTX - Durata Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia. As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin.

Receive DRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for DRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:DRTX
CUSIP26658A10
WebN/A
Phone+1-312-2197000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Durata Therapeutics (NASDAQ:DRTX) Frequently Asked Questions

What is Durata Therapeutics' stock symbol?

Durata Therapeutics trades on the NASDAQ under the ticker symbol "DRTX."

Has Durata Therapeutics been receiving favorable news coverage?

News headlines about DRTX stock have trended somewhat positive this week, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Durata Therapeutics earned a news impact score of 1.5 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days.

What other stocks do shareholders of Durata Therapeutics own?

How do I buy shares of Durata Therapeutics?

Shares of DRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Durata Therapeutics?

Durata Therapeutics' mailing address is 200 S Wacker Dr Ste 2550, CHICAGO, IL 60606-5811, United States. The biotechnology company can be reached via phone at +1-312-2197000.


MarketBeat Community Rating for Durata Therapeutics (NASDAQ DRTX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  121 (Vote Outperform)
Underperform Votes:  118 (Vote Underperform)
Total Votes:  239
MarketBeat's community ratings are surveys of what our community members think about Durata Therapeutics and other stocks. Vote "Outperform" if you believe DRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel